Recombinant Protein Market to Surpass US$ 6,691.4 Mn by 2030 - Coherent Market Insights

Global Recombinant Protein Market, by Product Type (Antibodies, Antigens, Enzymes, Hormones and Others), by Expression System (Microbes, Plant and Animal), by Application ( Drug Discovery and Development, Research Application, Therapeutic Use, Diagnostics, and Others), by End User (Biotechnology and Pharmaceutical Companies, Academic Research Institutes, Contract Research Organizations and Others), by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 2,808.4 Million in 2022 and is expected to exhibit a CAGR of 11.5% during the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.

The key players in the market are using various technologies and platforms in the recombinant protein production to reduce the overall cost of production and increase the production yield, which is expected to drive the market growth over the forecast period. The market players are adopting various strategies such as investments and acquisitions to get the exclusive rights of technology, and platforms for recombinant protein production. For instance, in June 2021, Vectron Biosolutions AS, a company developing and marketing vector technologies for the biotechnology and life science industries, announced that it had raised US$ 2.7 million in a Series A financing round led by Dynamk Capital along with the acquisition of a bacterial secretion platform from Utah, U.S.-based T3S TECHNOLOGIES, INC., a biotechnology company. The acquisition of T3S Technologies’ secretion platform combined with Vectron’s core expression technology and additional financing will significantly help Vectron to reduce costs associated with the production of recombinant proteins or solutions to advance their challenging proteins to the market.

Global Recombinant Protein Market– Impact of Coronavirus (COVID-19) Pandemic

The World Health Organization (WHO) designated the illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that first appeared in Wuhan (province of Hubei, China) in the last months of 2019 as "coronavirus disease 2019," or COVID-19. This virus spread quickly and had a serious negative impact on the economies, social behaviors, and health of every country in the world.

Governments of various countries are focusing on initiatives to fight against the COVID-19 pandemic and stop the spread of the coronavirus infection by implementing various measures in the countries. Countries such as U.A.E., the U.K., and others have implemented some measures and guidelines to reduce the spread of COVID-19 in the country. For instance, in December 2021, The Ministry of Health and Prevention (MoHAP) U.A.E. approved the emergency use of the Sinopharm CNBG's (China National Biotech Group) new recombinant protein vaccine, following the strict monitoring and evaluation of the data of the study conducted in the U.A.E. The ministry affirmed that the emergency use of the new vaccine is in full compliance with the regulations and laws for a faster review of licensing procedures. This was a part of the ministry's painstaking efforts, in cooperation with health authorities, to help in prevention of the Covid-19 pandemic in people. Thus, COVID-19 had a positive impact on recombinant protein market.

Global Recombinant Protein Market: Key Developments

In September 2022, Creative Enzymes, a company providing a variety of medical enzymes and industrial enzymes, announced the launch of Kex2 Protease from Saccharomyces cerevisiae, recombinant, for the cleavage of secreted peptides in yeast exogenous protein expression. Kex2 is a recombinant protease expressed by genetic engineering technology and is a calcium-dependent protein hydrolase that can specifically recognize and cleave the C terminal peptide bond of Arg-Arg, Lys-Arg.

 In June 2022, AMSBIO, a provider of quality life science research reagents and services, announced the launch of its StemFit Purotein range of recombinant proteins for cell therapy applications. The StemFit Purotein range includes recombinant proteins that play key roles in differentiating embryonic stem (ES) and induced pluripotent cells (iPS) in pancreas, heart, kidney, blood, and immune cells.

Browse 35 Market Data Tables and 97 Figures spread through 270 Pages and in-depth TOC on “Global Recombinant Protein Market”-  Forecast to 2030, by Product Type (Antibodies, Antigens, Enzymes, Hormones and Others), by Expression System (Microbes, Plant and Animal), by Application ( Drug Discovery and Development, Research Application, Therapeutic Use, Diagnostics, and Others), by End User (Biotechnology and Pharmaceutical Companies, Academic Research Institutes, Contract Research Organizations and Others) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/recombinant-protein-market-1516

Key Takeaways of the Global Recombinant Protein Market:

• The global recombinant protein market is expected to exhibit a CAGR of 11.5% during the forecast period. The key players in the market are adopting various inorganic strategies such as acquisitions to increase its production capacity of recombinant proteins and research and development capabilities, which is expected to drive the segment growth over the forecast period. For instance, in May 2022, QIAGEN, a provider of sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research, acquired Blirt.eu, a manufacturer of recombinant enzymes. Blirt.eu develops, manufactures, and commercializes standardized and customized solutions for proteins and enzymes as well as molecular biology reagents. The acquisition will add new research and development and manufacturing capabilities of QIAGEN’s for customized and standardized recombinant enzymes, as well as molecular biology reagents.
• In terms of Application, drug discovery and development segment is estimated to hold a dominant position in the global recombinant protein market over the forecast period. Owing to, market players are involved in strategies such as partnerships for antibody (a type of recombinant protein) production. For instance, in October 2021, Leinco Technologies, Inc., a contract development manufacturing organization (CDMO), and Vanderbilt University announced a partnership that will give Leinco exclusive rights to increase antibody production at VUMC, a center for infectious disease clinical research, diagnostics, therapeutics, and vaccine development.
• Among regions, North America is estimated to account for the largest market share in the global recombinant protein market over the forecast period, owing to increasing acquisitions by market players in the region. For instance, in January 2022, Thermo Fisher Scientific Inc., a company based in the U.S. that provides scientific equipment, reagents, and consumables as well as software services, and PeproTech, Inc., a company based in New Jersey, U.S., that develops and produces recombinant proteins such as cytokines and growth factors, announced that Thermo Fisher completed its acquisition of PeproTech on December 30, 2021 for a total cash purchase price of around US$ 1.85 billion.
• Major players operating in the global recombinant protein market includes Merck KGaA, OriGene Technologies, Inc., Thermo Fisher Scientific Inc., Feldan Therapeutics, ACROBiosystems, Abcam plc., Randox Laboratories Ltd., SOL GROUP, Proteintech Group, Inc, Planet Biotechnology, Inc., INFINITE ENZYMES, INC., ORF Genetics, GenScript, BTL Biotechno Labs Pvt Ltd., Prospec-Tany Technogene Ltd., BPS Bioscience, Inc., Sino Biological, Cape Bio Pharms, Abnova Corporation, GeNext Genomics.